Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Vulvar Neoplasms 1 Vulvar Diseases 1 Uterine Cervical Dysplasia 1 Papillomavirus Infections 1 Myeloproliferative Disorders 1 Carcinoma in Situ 1

Interventions

fludarabine phosphate 58 Cyclophosphamide 54 Peripheral Blood Stem Cell Transplantation 49 Mycophenolic Acid 39 Busulfan 38 Tacrolimus 37 Cyclosporine 33 Antilymphocyte Serum 33 Whole-Body Irradiation 32 Filgrastim 28 Methotrexate 27 Radiotherapy 20 Melphalan 18 Cytarabine 17 fludarabine 16 Etoposide 16 Methylprednisolone 14 ruxolitinib 11 sargramostim 9 Flow Cytometry 9 Cyclosporins 9 Cord Blood Stem Cell Transplantation 9 Alemtuzumab 9 thymoglobulin 8 Sirolimus 8 Psychiatric Rehabilitation 8 Granulocyte Colony-Stimulating Factor 8 Azacitidine 8 merphos 7 Decitabine 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Myeloproliferative Disorders × Hydroxyzine × Clear all

NCT03808805 2025-12-03

APHYPAP

University Hospital, Brest

Phase 3 Completed

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡